Do analysts prefer ABBV or DYAI?

AbbVie presently has a consensus price target of $296.88, suggesting a potential upside of 3.85%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Dyadic International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 6 Hold rating(s) 22 Buy rating(s) 1 Strong Buy rating(s) 2.83 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer ABBV or DYAI?

In the previous week, AbbVie had 114 more articles in the media than Dyadic International. MarketBeat recorded 115 mentions for AbbVie and 1 mentions for Dyadic International. AbbVie's average media sentiment score of 0.94 beat Dyadic International's score of 0.00 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 58 Very Positive mention(s) 18 Positive mention(s) 28 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DYAI or ABCL?

AbCellera Biologics has a consensus target price of $14.60, indicating a potential upside of 19.87%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Dyadic International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AbCellera Biologics 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82

Does the media refer more to DYAI or ABCL?

In the previous week, AbCellera Biologics had 4 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for AbCellera Biologics and 1 mentions for Dyadic International. AbCellera Biologics' average media sentiment score of 0.27 beat Dyadic International's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ABEO or DYAI?

In the previous week, Abeona Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Dyadic International. Abeona Therapeutics' average media sentiment score of 0.57 beat Dyadic International's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DYAI or ACIU?

AC Immune has a consensus price target of $7.50, indicating a potential upside of 258.85%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Dyadic International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer DYAI or ACIU?

In the previous week, AC Immune had 4 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for AC Immune and 1 mentions for Dyadic International. AC Immune's average media sentiment score of 0.36 beat Dyadic International's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACAD or DYAI?

ACADIA Pharmaceuticals presently has a consensus price target of $31.34, suggesting a potential upside of 52.37%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Dyadic International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.72 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ACAD or DYAI?

In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than Dyadic International. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 1 mentions for Dyadic International. ACADIA Pharmaceuticals' average media sentiment score of 0.13 beat Dyadic International's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyadic International (DYAI) Competitors

$0.36 -0.02 (-4.26%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$0.40 +0.04 (+9.72%)

As of 05:02 AM Eastern

Compare

DYAI vs. ABBV, ABCL, ABEO, ACIU, and ACAD

Should you buy Dyadic International stock or one of its competitors? Dyadic International's main competitors and comparable companies include AbbVie (ABBV), AbCellera Biologics (ABCL), Abeona Therapeutics (ABEO), AC Immune (ACIU), and ACADIA Pharmaceuticals (ACAD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyadic International compare to AbbVie?

AbbVie (NYSE:ABBV) and Dyadic International (NASDAQ:DYAI) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

AbbVie has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

AbbVie has a net margin of 15.67% compared to Dyadic International's net margin of -201.43%. AbbVie's return on equity of -435.41% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	15.67%	-435.41%	16.89%
Dyadic International	-201.43%	-2,920.31%	-84.77%

In the previous week, AbbVie had 114 more articles in the media than Dyadic International. MarketBeat recorded 115 mentions for AbbVie and 1 mentions for Dyadic International. AbbVie's average media sentiment score of 0.94 beat Dyadic International's score of 0.00 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	58 Very Positive mention(s)	18 Positive mention(s)	28 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbbVie presently has a consensus price target of $296.88, suggesting a potential upside of 3.85%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AbbVie has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	8.26	$4.23B	$5.81	49.20
Dyadic International	$3.09M	4.67	-$7.36M	-$0.23	N/A

Summary

AbbVie beats Dyadic International on 15 of the 17 factors compared between the two stocks.

How does Dyadic International compare to AbCellera Biologics?

Dyadic International (NASDAQ:DYAI) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Dyadic International has a net margin of -201.43% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

AbCellera Biologics has a consensus target price of $14.60, indicating a potential upside of 19.87%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, AbCellera Biologics had 4 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for AbCellera Biologics and 1 mentions for Dyadic International. AbCellera Biologics' average media sentiment score of 0.27 beat Dyadic International's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Dyadic International has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	4.67	-$7.36M	-$0.23	N/A
AbCellera Biologics	$75.13M	49.71	-$146.41M	-$0.54	N/A

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

AbCellera Biologics beats Dyadic International on 13 of the 17 factors compared between the two stocks.

How does Dyadic International compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

In the previous week, Abeona Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Dyadic International. Abeona Therapeutics' average media sentiment score of 0.57 beat Dyadic International's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics presently has a consensus target price of $21.00, suggesting a potential upside of 394.12%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Abeona Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Abeona Therapeutics has higher revenue and earnings than Dyadic International. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	41.76	$71.18M	-$1.09	N/A
Dyadic International	$3.09M	4.67	-$7.36M	-$0.23	N/A

Abeona Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Abeona Therapeutics' return on equity of -41.69% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Abeona Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Abeona Therapeutics beats Dyadic International on 13 of the 16 factors compared between the two stocks.

How does Dyadic International compare to AC Immune?

Dyadic International (NASDAQ:DYAI) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AC Immune has a consensus price target of $7.50, indicating a potential upside of 258.85%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, AC Immune had 4 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for AC Immune and 1 mentions for Dyadic International. AC Immune's average media sentiment score of 0.36 beat Dyadic International's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	4.67	-$7.36M	-$0.23	N/A
AC Immune	$4.31M	49.35	-$85.03M	-$0.54	N/A

Dyadic International has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Dyadic International has a net margin of -201.43% compared to AC Immune's net margin of -245.32%. AC Immune's return on equity of -100.17% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
AC Immune	-245.32%	-100.17%	-28.36%

Summary

AC Immune beats Dyadic International on 11 of the 15 factors compared between the two stocks.

How does Dyadic International compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Dyadic International (NASDAQ:DYAI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.31	$391M	$2.22	9.27
Dyadic International	$3.09M	4.67	-$7.36M	-$0.23	N/A

ACADIA Pharmaceuticals presently has a consensus price target of $31.34, suggesting a potential upside of 52.37%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.72
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ACADIA Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than Dyadic International. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 1 mentions for Dyadic International. ACADIA Pharmaceuticals' average media sentiment score of 0.13 beat Dyadic International's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Dyadic International's net margin of -201.43%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Dyadic International	-201.43%	-2,920.31%	-84.77%

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Dyadic International on 14 of the 16 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.06M	$4.14B	$7.81B	$12.08B
Dividend Yield	N/A	3.63%	2.48%	4.41%
P/E Ratio	-1.57	37.09	37.57	30.52
Price / Sales	4.67	17.12	8.87	5.88
Price / Cash	N/A	26.76	21.63	22.81
Price / Book	12.00	4.49	4.78	4.05
Net Income	-$7.36M	-$22.13M	$3.50B	$381.51M
7 Day Performance	-8.65%	-3.00%	-2.29%	-2.44%
1 Month Performance	-21.02%	-8.58%	-5.36%	-7.02%
1 Year Performance	-65.71%	3.36%	1.23%	-5.71%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	0.3225 of 5 stars	$0.36 -4.3%	N/A	-66.7%	$15.06M	$3.09M	N/A	5	Gap Down
ABBV AbbVie	4.4412 of 5 stars	$286.70 0.0%	$279.86 -2.4%	+34.8%	$0.00	N/A	80.99	57,000	Trending News Earnings Report Dividend Increase Analyst Forecast High Trading Volume
ABCL AbCellera Biologics	2.4336 of 5 stars	$12.83 +6.2%	$13.89 +8.3%	+126.8%	$0.00	N/A	N/A	562	Upcoming Earnings High Trading Volume
ABEO Abeona Therapeutics	2.8642 of 5 stars	$4.45 +3.2%	$21.00 +371.9%	-11.1%	$0.00	N/A	N/A	226	Positive News Upcoming Earnings High Trading Volume
ACIU AC Immune	3.1787 of 5 stars	$2.25 -2.6%	$7.50 +233.3%	-34.3%	$0.00	N/A	N/A	106	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 11/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. ABBV, ABCL, ABEO, ACIU, and ACAD

How does Dyadic International compare to AbbVie?

Summary

How does Dyadic International compare to AbCellera Biologics?

Summary

How does Dyadic International compare to Abeona Therapeutics?

Summary

How does Dyadic International compare to AC Immune?

Summary

How does Dyadic International compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. ABBV, ABCL, ABEO, ACIU, and ACAD

How does Dyadic International compare to AbbVie?

Which has more volatility & risk, ABBV or DYAI?

Is ABBV or DYAI more profitable?

Does the media prefer ABBV or DYAI?

Do analysts prefer ABBV or DYAI?

Do insiders & institutionals hold more shares of ABBV or DYAI?

Which has preferable valuation and earnings, ABBV or DYAI?

Summary

How does Dyadic International compare to AbCellera Biologics?

Is DYAI or ABCL more profitable?

Do analysts prefer DYAI or ABCL?

Does the media refer more to DYAI or ABCL?

Which has more volatility and risk, DYAI or ABCL?

Which has higher earnings and valuation, DYAI or ABCL?

Do institutionals and insiders believe in DYAI or ABCL?

Summary

How does Dyadic International compare to Abeona Therapeutics?

Does the media prefer ABEO or DYAI?

Do analysts prefer ABEO or DYAI?

Which has stronger valuation and earnings, ABEO or DYAI?

Is ABEO or DYAI more profitable?

Which has more volatility and risk, ABEO or DYAI?

Do insiders & institutionals hold more shares of ABEO or DYAI?

Summary

How does Dyadic International compare to AC Immune?

Do institutionals and insiders believe in DYAI or ACIU?

Do analysts recommend DYAI or ACIU?

Does the media prefer DYAI or ACIU?

Which has stronger valuation & earnings, DYAI or ACIU?

Which has more volatility and risk, DYAI or ACIU?

Is DYAI or ACIU more profitable?

Summary

How does Dyadic International compare to ACADIA Pharmaceuticals?

Which has better valuation & earnings, ACAD or DYAI?

Do analysts prefer ACAD or DYAI?

Which has more volatility and risk, ACAD or DYAI?

Does the media favor ACAD or DYAI?

Is ACAD or DYAI more profitable?

Do institutionals and insiders have more ownership in ACAD or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools